Protagonist Therapeutics Reports Granting of Inducement Awards

Rhea-AI Summary

Protagonist Therapeutics (Nasdaq:PTGX) granted inducement awards on April 15, 2026 to two newly hired employees under its Amended and Restated Inducement Plan.

The awards total options for 55,425 shares and RSUs for 14,425 shares; option exercise price is $105.44, equal to the April 15, 2026 closing price. Vesting spans four years. Awards were approved by the compensation committee and granted in accordance with Nasdaq Rule 5635(c)(4).

News Market Reaction – PTGX

+2.17%

1 alert

+2.17% News Effect

On the day this news was published, PTGX gained 2.17%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 55,425 shares Inducement RSUs: 14,425 shares Option exercise price: $105.44 +5 more

8 metrics

Inducement options 55,425 shares Aggregate options granted to two new employees under inducement plan

Inducement RSUs 14,425 shares Aggregate restricted stock units granted to two new employees

Option exercise price $105.44 Per-share closing price on Nasdaq Global Market on April 15, 2026

Option vesting period 4 years 25% after one year; remainder in equal monthly installments over three years

RSU vesting period 4 years One-fourth of RSU shares vest annually

Plan adoption date May 29, 2018 Original adoption of Amended and Restated Inducement Plan

Plan amendments Feb 18, 2020; Feb 15, 2022 Dates the inducement plan was amended

24h price change 0.69% Move in PTGX share price prior to this announcement

Market Reality Check

Price: $100.00 Vol: Volume 763,200 vs 20-day ...

normal vol

$100.00 Last Close

Volume Volume 763,200 vs 20-day average 978,605 (relative volume 0.78) suggests quieter trading ahead of this HR-related update. normal

Technical Shares trade above the 200-day MA, with price at 105.44 vs 200-day MA of 76.8, and sit 2.23% below the 52-week high of 107.84.

Peers on Argus

PTGX was up 0.69% while peers showed mixed moves: ZLAB +3.52%, AKRO +0.24%, and ...

PTGX was up 0.69% while peers showed mixed moves: ZLAB +3.52%, AKRO +0.24%, and MIRM, AAPG, MTSR modestly negative. No coordinated biotechnology sector move is indicated.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	FDA approval	Positive	-0.1%	FDA approved ICOTYDE for plaque psoriasis with milestones and royalties owed.
Mar 02	Regulatory milestone	Positive	+2.4%	FDA accepted rusfertide NDA and granted Priority Review for polycythemia vera.
Feb 25	Earnings update	Negative	-0.3%	2025 revenue declined and net loss reported despite strong cash position.
Feb 25	Earnings update	Negative	-0.3%	Detailed 2025 financials with lower collaboration revenue and notable net loss.
Feb 24	Investor conferences	Neutral	+0.9%	CEO scheduled to present at multiple investment bank conferences in March.

Pattern Detected

Recent major catalysts (FDA and NDA events, earnings, conferences) mostly saw price reactions aligned with the news tone, with only one mild divergence on an FDA approval.

Recent Company History

Over recent months, Protagonist reported multiple key milestones: a U.S. FDA approval for ICOTYDE with associated $50 million milestone and future royalties, an FDA Priority Review acceptance for rusfertide, and Q4/FY 2025 results highlighting $646.0M cash and lower 2025 revenue. The stock generally reacted modestly in line with these catalysts. Against that backdrop, this inducement-award announcement reflects routine equity-based hiring activity rather than a major pipeline or financial inflection point.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-08-06

The company has an effective S-3ASR shelf registration dated 2025-08-06, expiring on 2028-08-06, with 0 recorded uses in the provided data. This indicates an available but so far unused capacity to issue registered securities, without any specific amounts or recent takedowns disclosed here.

Market Pulse Summary

This announcement details standard inducement equity awards—options on 55,425 shares at an exercise ...

Analysis

This announcement details standard inducement equity awards—options on 55,425 shares at an exercise price of $105.44 and 14,425 RSUs—vesting over 4 years under an existing inducement plan. It follows recent major events such as FDA approval of ICOTYDE and Priority Review for rusfertide. Investors may monitor future SEC filings for additional equity grants or insider activity, and track progress on the company’s approved and late-stage assets.

Key Terms

restricted stock units, rsus, exercise price, nasdaq global market, +2 more

6 terms

restricted stock units financial

"and restricted stock units (RSUs) to acquire 14,425 shares of Protagonist"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"and restricted stock units (RSUs) to acquire 14,425 shares of Protagonist"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

exercise price financial

"The exercise price of the options is $105.44, which was the per-share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq global market regulatory

"per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on April 15, 2026."

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

inducement plan financial

"granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

vesting financial

"shares subject to each option vest over a four-year period, with 25 percent of the shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 55,425 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 14,425 shares of Protagonist Therapeutics common stock. The exercise price of the options is $105.44, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on April 15, 2026. The shares subject to each option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of the employee's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE^™ (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc., a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

FAQ

What inducement awards did Protagonist Therapeutics (PTGX) grant on April 15, 2026?

They granted options for 55,425 shares and RSUs for 14,425 shares to two new hires. According to Protagonist Therapeutics, the awards were issued under the company's Inducement Plan and approved by the compensation committee.

What is the exercise price and how was it set for PTGX inducement options?

The exercise price is $105.44, equal to the April 15, 2026 closing price. According to Protagonist Therapeutics, the price reflects the per-share closing price on Nasdaq on the grant date.

How do the PTGX stock option vesting schedules work for the April 15, 2026 awards?

Options vest over four years with 25% after one year, then monthly over three years. According to Protagonist Therapeutics, RSUs vest one-fourth annually across four years.

Under what authority were the PTGX inducement awards granted on April 15, 2026?

They were granted as material inducements under Nasdaq Marketplace Rule 5635(c)(4). According to Protagonist Therapeutics, the awards complied with the company's Inducement Plan and received compensation committee approval.

How many employees received inducement awards from Protagonist Therapeutics on April 15, 2026?

Two recently hired employees received the inducement awards on April 15, 2026. According to Protagonist Therapeutics, the grants were made in accordance with their employment offer letters.

Will the PTGX inducement awards likely dilute existing shareholders and by how much?

The company disclosed awards totaling 69,850 shares subject to options and RSUs, which could dilute shares when vested and exercised. According to Protagonist Therapeutics, impact depends on future vesting, exercise, and overall share count.